Skip to content
DataLookout
Menu

HMBeaconNCT07575308

HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 21 → 29 locations
  2. Minor Trial sites expanded: 11 → 21 locations
    • Study completion pushed from Nov 29, 2028 to Aug 30, 2029
  3. Notable Eligibility criteria expanded, about 8 words
    • Trial sites expanded: 4 → 11 locations
  4. Notable Recruitment opened
    • Trial sites expanded: 1 → 4 locations
    • Start date changed from estimate of Jul 31, 2026 to Jul 30, 2026
    v5
  5. Notable Start date: Jun 30, 2026 to Jul 31, 2026v4
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Start date: May 22, 2026 to Jun 30, 2026v3
  2. Minor Start date: May 5, 2026 to May 22, 2026v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Frequency of Adverse Events
Timeframe: Up to Week 72

Secondary (5)

Change from Baseline in Plasminogen (PLG) Plasma Activity Levels
Change from Baseline in PLG Plasma Protein Levels
Change from Baseline in Menstrual Blood Loss Via Pictorial Blood Assessment Chart (PBAC)
Patient-reported Outcome (PRO) assessed by Patient Global Impression of Change (PGI-C) Score
Change from Baseline in PRO assessed by Patient Global Impression of Severity (PGI-S) Score

Arms and interventions

ALN-6400 (Treatment Group A)Experimental

Participants will be administered multiple doses of ALN-6400.

ALN-6400 (Treatment Group B)Experimental

Participants will be administered multiple doses of ALN-6400.

Drugs: ALN-6400

Sites

29 sites in 6 countries

United States 10, United Kingdom 7, Turkey (Türkiye) 5, Germany 4, Netherlands 2, Sweden 1